Smith & Nephew SNATS, Inc. Plans Dividend of $0.48 (NYSE:SNN)

Smith & Nephew SNATS, Inc. (NYSE:SNN) announced a dividend on Thursday, March 5th. Stockholders of record on Friday, March 27th will be paid a dividend of 0.482 per share by the medical equipment provider on Wednesday, May 27th. This represents a dividend yield of 281.0%. The ex-dividend date is Friday, March 27th.

Smith & Nephew SNATS has increased its dividend by an average of 0.0%per year over the last three years. Smith & Nephew SNATS has a dividend payout ratio of 26.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Smith & Nephew SNATS to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.57 annual dividend with an expected future payout ratio of 28.5%.

Smith & Nephew SNATS Trading Down 1.6%

Shares of NYSE SNN traded down $0.56 during mid-day trading on Friday, reaching $34.29. The company had a trading volume of 440,099 shares, compared to its average volume of 955,770. The firm has a 50 day simple moving average of $34.40 and a two-hundred day simple moving average of $34.95. Smith & Nephew SNATS has a 52-week low of $23.91 and a 52-week high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60.

Analysts Set New Price Targets

A number of research firms have recently commented on SNN. Wall Street Zen downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research note on Monday, December 15th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Canaccord Genuity Group raised their price objective on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the stock a “hold” rating in a research report on Thursday. Finally, Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Smith & Nephew SNATS presently has a consensus rating of “Hold” and an average target price of $36.25.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.